NextCure Closes All-Stock Merger With Avere Therapeutics to Target Oral IL-23 Inflammatory Disease Market

The Quick Take

• NextCure (NXTC) and Avere Therapeutics finalized a definitive all-stock merger agreement
• Avere develops oral therapies targeting IL-23 driven diseases in a $16B+ injectable-dominated market
• NXTC shares volatile as investors weigh all-stock dilution against transformative pipeline potential

NextCure, a Nasdaq-listed clinical-stage biopharmaceutical company, has finalized an all-stock merger agreement with privately held Avere Therapeutics, a biotech focused on developing oral therapies targeting interleukin-23 driven inflammatory diseases. IL-23 is among the most commercially validated cytokine targets in modern immunology—injectable IL-23 inhibitors from Johnson & Johnson (Tremfya, ~$4B annual revenue) and AbbVie (Skyrizi, ~$12B annual revenue) dominate the biologic category. Avere's oral formulation thesis addresses a persistent clinical gap: patients with psoriasis, Crohn's disease, and ulcerative colitis overwhelmingly prefer oral maintenance therapy, and no approved oral IL-23 inhibitor currently exists.

The NXTC all-stock merger reflects broader biotech M&A dynamics where mid-cap platforms with capital constraints acquire private assets to access novel mechanisms without upfront cash. NXTC shareholders gain exposure to a potentially transformative oral IL-23 asset but face dilution risk typical of all-stock combinations. The transaction's strategic logic mirrors precedents—AstraZeneca's acquisition of Alexion and Bristol-Myers' pickup of Karuna—where established mechanisms in new formulation formats commanded significant valuation premiums upon clinical data readouts. Institutional investor reaction will hinge on Avere's clinical development stage and proximity to human proof-of-concept data.

Key milestones to watch post-merger include IND filings or Phase 1 initiation for Avere's oral IL-23 candidate, the combined entity's cash runway, and whether strategic pharma players express interest in the pipeline. Biotech analysts hold that proof-of-concept oral IL-23 data could catalyse significant share price re-rating, as the addressable market across autoimmune indications exceeds $30 billion annually. However, clinical attrition rates in small-molecule immunology remain high, and NXTC's ability to fund development to value-creating milestones will be the central question for investors assessing entry risk.

Synthesized from 2 sources.